Search
for
Sort by
Research 31–60 of 1000+
- Efficacy and safety of tofacitinib therapy in Asian patients with severe alopecia areata
- Oral Tofacitinib and Systemic Corticosteroids, Alone or in Combination, in Patients With Moderate-to-Severe Alopecia Areata: A Retrospective Study
- Treatment of Severe Alopecia Areata: Combination Therapy Using Systemic Cyclosporine A with Low Dose Corticosteroids
- Successful Treatment of Severe Alopecia Areata With Oral or Topical Tofacitinib.
- Five Cases of Severe Alopecia Areata Treated with Gagamhwajung-hwan
- Comparative efficacy and safety of systemic steroids, oral JAK inhibitors and Contact Immunotherapy in the Treatment of severe alopecia areata: a systematic review and network meta-analysis
- 41701 Efficacy of the Oral JAK1/JAK2 Inhibitor CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata: Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 Phase 3 Trial
- Ritlecitinib for Severe Alopecia Areata: A 24-Week, Multicentre, Real-World Study
- Complete hair regrowth in a patient with severe alopecia areata treated with deucravacitinib
- Treatments for Moderate-to-Severe Alopecia Areata: A Systematic Narrative Review
- Baricitinib: A Review in Severe Alopecia Areata
- Ex Vivo Treatment with Allogenic Mesenchymal Stem Cells of a Healthy Donor on Peripheral Blood Mononuclear Cells of Patients with Severe Alopecia Areata: Targeting Dysregulated T Cells and the Acquisition of Immunotolerance
- Treatment of severe alopecia areata with oral tofacitinib: A case series
- 378 Treatment of severe alopecia areata with the oral Janus kinase inhibitor, tofacitinib: A retrospective chart review
- TREATMENT OF SEVERE ALOPECIA AREATA USING METHOTREXATE AS AN ADJUNCTIVE DRUG IN COMBINATION WITH INTRAVENOUS AND ORAL CORTICOSTEROID
- Upadacitinib for Severe Alopecia Areata in Adults and Adolescents
- 75893 Long-term efficacy, complete scalp hair regrowth and normal body hair/nails in adolescents with severe alopecia areata (AA) receiving ritlecitinib up to 3 years in the ALLEGRO clinical trials
- A Cost-per-Responder Analysis of Ritlecitinib vs Baricitinib in Severe Alopecia Areata
- High-Dose Baricitinib for Severe Alopecia Areata with Suboptimal Response to Conventional Therapy: A Real-World Assessment
- BH31 Ritlecitinib for severe alopecia areata: does regional prescribing match national guidance?
- Circulating MicroRNA Signatures in Severe Alopecia Areata: Diagnostic Discrimination, Pathway Analysis, and Therapeutic Implications
- Effectiveness of baricitinib in severe alopecia areata in real life
- Circulating MicroRNA Signatures in Severe Alopecia Areata: Diagnostic Discrimination, Pathway Analysis, and Therapeutic Implications
- Successful treatment of severe diffuse alopecia areata with abrocitinib
- Effectiveness of baricitinib in severe alopecia areata in real life: a retrospective study of 87 patients
- 52709 Patient-Reported Outcomes for Scalp, Eyebrow and Eyelash Hair Loss in Patients with Severe Alopecia Areata Treated with Baricitinib: 152 Week Results from two Phase 3 Clinical Trials
- Ritlecitinib in severe alopecia areata: a profile of its use
- Abrocitinib Improved Dupilumab-Resistant Severe Atopic Dermatitis with Comorbid Mild Alopecia Areata in a 12-Year-Old Boy: A Case Report with 1-Year Follow-Up
- Baricitinib Demonstrates Rapid Action Within Just 2 Months of Treatment in Severe and Unresponsive Alopecia Areata: A Case Report
- Patient-Reported Burden of Severe Alopecia Areata: First Results from the Multinational Alopecia Areata Unmet Need Survey